Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;28(1):210-2.
doi: 10.1038/leu.2013.216. Epub 2013 Jul 17.

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

C Touzeau  1 , C Dousset  2 , S Le Gouill  3 , D Sampath  4 , J D Leverson  5 , A J Souers  5 , S Maïga  6 , M C Béné  7 , P Moreau  8 , C Pellat-Deceunynck  6 , M Amiot  6
Affiliations
Free PMC article

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

C Touzeau et al. Leukemia. 2014 Jan.
Free PMC article
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Sensitivity to ABT-199 of HMCLs according to different molecular subgroups. (b) Sensitivity of HMCLs to ABT-199 compared to ABT-737. P-value was determined using Mann–Whitney test. For a and b, 25 HMCLs (respectively 8 CCND1 (KMS-12-PE, KMS-12-BM, SKMM-2, Karpas 620, U-266, XG-1, XG-5, NAN-7), 7 MAF (JJN-3, MM.1S, L-363, RPMI 8266, XG-6, BCN, NAN-1,) 7 MMSET (JIM-3, LP-1, OPM-2, NCI-H929, KMS-11, XG-7, NAN-3,) and 3 non recurrent translocation (XG-2, KMM-1, AMO1)) cell lines were cultured with increasing doses of ABT-199 or ABT-737 during 48 h. Cell death was assessed by APO 2.7 staining. LD50 was determined for each cell line. White symbols indicate wild-type P53 HMCL and black symbols indicate abnormal P53 HMCL (c) ABT-199 disrupts BH3-only/Bcl-2 heterodimers but not BH3-only/Bcl-xL heterodimers. Karpas 620 were treated or not for 6 h with 25 nM ABT-199. Lysate (600 μg) and immunoprecipitation were done as previously described using the indicated antibodies. The immunoprecipitates were analyzed for the presence of BH3-only. (d) The Bcl-2/Mcl-1 mRNA ratio discriminates cell lines sensitive or resistant to ABT-199. Quantitative PCR was performed using the following TaqMan probes (BCL2 (Hs00608023_m1), MCL1 (Hs00172036_m1) and RPL37a (Hs01102345_m1). The relative expression of Bcl-2 and Mcl-1 mRNA was calculated according to the equation of Pfaffl and normalized to JJN3 cell line. Sensitive HMCL were defined by a LD50 inferior to 100 nM. P-value was determined using Mann–Whitney test. (e) The LP-1 cell line was transfected with either si Control (Ct) or si Mcl-1. Following 48 h transfection, the protein level of Mcl-1 was assessed by immunoblotting, and cells were treated with ABT-199 for a further 48 h. Cell death was quantified by APO 2.7 staining. P-value was determined using paired Student's t-test. **P<0.008.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Labi V, Grespi F, Baumgartner F, Villunger A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy. Cell Death Differ. 2008;6:977–987. - PMC - PubMed
    1. Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118:3901–3910. - PubMed
    1. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;5:375–388. - PubMed
    1. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;5:488–496. - PMC - PubMed
    1. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;2:202–208. - PubMed